NCT05078905 Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
| NCT ID | NCT05078905 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Condition | COVID-19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2021-10-13 |
| Primary Completion | 2050-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2021-10-13 with a primary completion date of 2050-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Vaccines against SARS-CoV-2, the virus that causes COVID-19, have been highly effective against preventing severe disease. But the protective effects of these vaccines appear to wane over time. Researchers want to learn why. Objective: To learn more about how the immune system responds to vaccines against infections like SARS-CoV-2. Eligibility: Healthy adults ages 18 or older who are scheduled to receive either a new vaccine or a booster shot against SARS-COV-2 or another emerging infection. Design: Participants will be screened with a medical history and blood and urine tests. Participants will have up to 8 study visits in 1 year. Each visit should last less than 2 hours. At each visit, participants will give blood samples. Some blood samples will be used for genetic testing. They will also give updates on their health. After the first study visit, participants will receive either a first vaccination or a booster shot. They must get the vaccine in their community or workplace. They will not get the vaccine at NIH. This study currently focuses on SARS-CoV-2, but it will expand to other infectious diseases as they emerge and become the target of new vaccines. ...
Eligibility Criteria
* INCLUSION CRITERIA: General Inclusion Criteria for All Groups: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Age 18 years or older 3. Hemoglobin \>= 9.0 grams per deciliter (g/dL) or \>= 11.2 for women who are pregnant. 4. Willingness to give consent for the storage of blood samples for research 5. Ability of subject to understand and the willingness to sign a written informed consent document Inclusion Criteria for Primary (New) Vaccination Group: 1\. No history of having received a dose of the vaccine for the infectious disease being studied. Subjects who have enrolled under another Laboratory of Immunoregulation (LIR) protocol and had samples drawn prior to vaccination will also be eligible for enrollment. Inclusion Criteria for Secondary (Booster) Vaccination Group: 1\. Willingness to return for baseline research blood collection prior to booster vaccination. EXCLUSION CRITERIA: 1. Current abuse of alcohol or other drugs that, in the judgement of the Principal Investigator (PI) could interfere with patient compliance. 2. Any medical or mental health condition that, in the judgement of the PI, would make the volunteer unable to participate in the study.
Contact & Investigator
Susan L Moir, Ph.D.
PRINCIPAL INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Frequently Asked Questions
Who can join the NCT05078905 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COVID-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05078905 currently recruiting?
Yes, NCT05078905 is actively recruiting participants. Contact the research team at cseamon@cc.nih.gov for enrollment information.
Where is the NCT05078905 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT05078905 clinical trial?
NCT05078905 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The principal investigator is Susan L Moir, Ph.D. at National Institute of Allergy and Infectious Diseases (NIAID). The trial plans to enroll 1,200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.